Navigation Links
Simvastatin Leads Pfizer's Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
Date:5/13/2008

Results from the ENHANCE Trial Impacting Physician Prescribing Patterns,

According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that simvastatin (Merck's Zocor, generics) leads Pfizer's Lipitor in second-line patient share -- 22.9 percent versus 14.7 percent. Most patients progressing to simvastatin do so after switching from Lipitor. Surveyed primary care physicians and cardiologists cite simvastatin's better reimbursement and formulary status as the primary reason to prescribe simvastatin instead of Lipitor. Nevertheless, despite the availability of generic statins, more than 75 percent of Lipitor's prescriptions stem from first-line therapy.

The report entitled Treatment Algorithms in Dyslipidemia also finds that, prior to the release of the ENHANCE trial results, Merck/Schering-Plough's Vytorin and AstraZeneca's Crestor also gained significant second-line patient shares-13.1 percent and 10.9 percent, respectively. These gains reflect physicians' efforts to boost efficacy in patients whose initial low-density lipoprotein (LDL) lowering treatment had been less than optimal; surveyed physicians perceive these agents to offer the best LDL-reducing ability. However, 47 percent of surveyed primary care physicians and 49 percent of surveyed cardiologists have changed their prescribing of Merck/Schering- Plough's Zetia and Vytorin because of data from the ENHANCE trial, which showed that the addition of Zetia to simvastatin treatment did not significantly change carotid artery thickness. The majority of surveyed physicians now prescribe Vytorin and Zetia in fewer new patients, with a smaller percentage of physicians switching patients off of these drugs.

"Cardiologists we surveyed expect to decrease their first- and second-line prescriptions for Vytorin between 2008 and 2010,
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
2. Nursing professor leads the way for telepsychiatry by nurses to treat postpartum depression
3. Prisoner HIV program leads to continuum of medical care after release
4. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
5. Minimally invasive pancreas surgery leads to fewer complications, study finds
6. UQ leads the way on complementary medicine research
7. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
8. When positive thinking leads to financial irresponsibility like compulsive gambling
9. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
10. Eli Manning Leads March for Babies in Manhattan
11. MRI before surgery leads to better-adapted treatment for breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewsw...se consumers a bronzed body year-round, but the ul...serious health risks. ,, (Logo: http://www.ne...Although some people think that a tan gives them a..." says Sharon Miller, M.S.E.E., a Food and Drug Ad...
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 /PRNewswire...ng about gifts for the holidays. For a loved one w... family members and friends oftentimes struggle wi... Living , one of the leading providers of senior l...er,s and dementia care , offers these suggestions....
(Date:11/30/2009)... , PHILADELPHIA, ...- , - Exclusive Updates From Elsevier,s T...eform and ARRA Momentum , Elsevier, a wor...s well,as web-based and electronic health record (...nline resource center for American Recovery and Re...
(Date:11/30/2009)...he European Association of Urology (EAU) and Europ...ght against prostate cancer, have entered into an,... commitment to increase and improve,patient aware...., Professor Per-Anders Abrahamsson, Secretary-G...iliated partnership, Europa Uomo will gain access ...
(Date:11/30/2009)...CAGONovember 30, 2009A pet owner knows the enormou...cially in troubled times. Most pets are considered... companions. A growing body of research now docume...velopment, elderly care, mental illness, physical ...nd the rehabilitation of incarcerated youth and ad...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:The therapeutic benefits of the human-animal bond 2
...17-year old Irish girl who made headlines recently... by asserting her right to abort has got the nod ...the Court demanding that she be allowed to go to B...the foetus she is carrying suffers from anencephal...
...new vaccine aimed at preventing cervical cancer is...s of the human papillomavirus (HPV) responsible f...ionwide study of the vaccine will be published in ...ine marketed by Merck under the name Gardasil coul...
...combination of molecular-targeted therapy and horm...earch for those seeking an effective treatment fo... International Journal of Gynecological Cancer. ...tumors, says review author Dr. Siqing Fu, an assis...
...dia is home to over 76.6 million people over the a...e health ministry, the country has 76,622,321 per...cent of the elderly population, Uttar Pradesh tops... have 5.5 million senior citizens each. De...
... line with Ranbaxy Laboratories aggressive interna... Africa's Competition Commission has solidified th...mited ("Be-Tabs") by Ranbaxy Laboratories. (RNBV).... Ranbaxy Laboratories Limited, headquartered...
...alth authorities in the US are worried about yet a...quito-spread infection. Rudy Bueno, the Chi...id that the situation may worsen if people don't f...ellants or going out at night in short-sleeve shir...
Other Medicine News:Health News:Pregnant Irish Teenager Wins the Right to Abort 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2Health News:Ranbaxy Labs Extends Roots in South Africa 2Health News:Ranbaxy Labs Extends Roots in South Africa 3Health News:Health Authorities Fear West Nile Season Again in US 2
(Date:11/30/2009)...30 Decision Resources, one of the ...ng on pharmaceutical and healthcare issues, foreca...ia will grow nine percent annually over the 2008 -... This growth will be driven mainly by increased go...of more-expensive therapies like pegylated interfe...
(Date:11/30/2009)...30 The U.S. Food and Dru... (duloxetine HCl) for the maintenance treatment of... Lilly and Company (NYSE: LLY ) announced today....a chronic illness, it is important that doctors an...ffective in both the acute and maintenance phase o...
(Date:11/30/2009)...30 Sanofi-aventis U.S. a...ng agreement with Intelliject, Inc. for a novel ep...t of allergic reactions (anaphylaxis) in North Ame...have this opportunity to offer this innovative del... risk of this life-threatening allergic reaction e...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 1DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 2Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2New research shows versatility of amniotic fluid stem cells 61908 1New research shows versatility of amniotic fluid stem cells 61908 2
....Va., May 27 The Blanchette Rockefeller Neuroscie...tions, Inc. (Inverness, NYSE: IMA ) of Waltham, M... and health management, announced today that they ...alize a diagnostic test for Alzheimer,s disease fi...RNI test, once fully commercialized, could dramati...
...., May 26 Theranostics Health, Inc. (TH) is pleas...ical research study funded by the Susan G. Komen F...was the recipient of a Promise Grant, part of over...09 to further the development of new prevention an...san G. Komen for the Cure(R) is a nonprofit organi...
Other Medicine Technology:Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 2Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 3Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 4Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 2Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 3
...ly 1990s, the "Reversed" shoulder prosthesis has b...success. More recently, an ever-growing number of ...on this prosthesis and the associated surgical tec...is the result of nearly fifteen years of clinical ...
AMINCO-Bowman Series 2 (AB2) Spectrofluorometer
SPEX Fluorolog-3
Gemini XPS Microplate Spectrofluorometer
Medicine Products: